Hepatitis E virus serology and PCR : does the methodology matter?
- Author
- Lien Cattoir (UGent) , FREDERIK VAN HOECKE (UGent) , Tom Van Maerken (UGent) , Eveline Nys (UGent) , Inge Ryckaert (UGent) , Matthias De Boulle, Anja Geerts (UGent) , Xavier Verhelst (UGent) , Isabelle Colle (UGent) , Veronik Hutse, Vanessa Suin, Magali Wautier, Steven Van Gucht (UGent) , Hans Van Vlierberghe (UGent) and Elizaveta Padalko (UGent)
- Organization
- Abstract
- Hepatitis E virus (HEV) genotype 3 is an emerging pathogen in the developed world. As the clinical manifestations and routine laboratory parameters are often nonspecific, accurate diagnostic tests are crucial. In the current study, the performance of six serological assays and three PCR assays for the detection of HEV was evaluated. In the setting of the Ghent University Hospital, patients with clinically suspected HEV infection were tested for the presence of HEV IgM and IgG as well as HEV RNA. Serology was performed using six commercial HEV ELISA assays: Biorex, Wantai and Mikrogen IgM and IgG. HEV RNA was detected using one commercial assay (Altona RealStarA (R)), and two optimized in-house real-time RT-PCR assays (according to Jothikumar et al., 2006 and Gyarmati et al., 2007). In addition, all three PCR assays were performed on 16 external quality control (EQC) samples. In a period of 39 months (January 2011-April 2014), 70 patients were enrolled. Using different ELISA assays, the prevalence of antibodies varied from 5.7% to 14.3% for HEV IgM and from 15.7% to 20.0% for IgG. All but two of the results of the PCR assays performed on clinical samples agreed. However, 10 out of 16 EQC samples results showed major discrepancies. We observed important differences in the performance of various serological and PCR assays. For this reason, results of both serological and molecular tests for HEV should be interpreted with caution.
- Keywords
- DEVELOPED-COUNTRIES, EMERGING INFECTION, ASSAYS, PERFORMANCE, DIAGNOSIS, DISEASE, RNA
Downloads
-
(...).pdf
- full text
- |
- UGent only
- |
- |
- 610.23 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-8530523
- MLA
- Cattoir, Lien, et al. “Hepatitis E Virus Serology and PCR : Does the Methodology Matter?” ARCHIVES OF VIROLOGY, vol. 162, no. 9, 2017, pp. 2625–32, doi:10.1007/s00705-017-3395-0.
- APA
- Cattoir, L., VAN HOECKE, F., Van Maerken, T., Nys, E., Ryckaert, I., De Boulle, M., … Padalko, E. (2017). Hepatitis E virus serology and PCR : does the methodology matter? ARCHIVES OF VIROLOGY, 162(9), 2625–2632. https://doi.org/10.1007/s00705-017-3395-0
- Chicago author-date
- Cattoir, Lien, FREDERIK VAN HOECKE, Tom Van Maerken, Eveline Nys, Inge Ryckaert, Matthias De Boulle, Anja Geerts, et al. 2017. “Hepatitis E Virus Serology and PCR : Does the Methodology Matter?” ARCHIVES OF VIROLOGY 162 (9): 2625–32. https://doi.org/10.1007/s00705-017-3395-0.
- Chicago author-date (all authors)
- Cattoir, Lien, FREDERIK VAN HOECKE, Tom Van Maerken, Eveline Nys, Inge Ryckaert, Matthias De Boulle, Anja Geerts, Xavier Verhelst, Isabelle Colle, Veronik Hutse, Vanessa Suin, Magali Wautier, Steven Van Gucht, Hans Van Vlierberghe, and Elizaveta Padalko. 2017. “Hepatitis E Virus Serology and PCR : Does the Methodology Matter?” ARCHIVES OF VIROLOGY 162 (9): 2625–2632. doi:10.1007/s00705-017-3395-0.
- Vancouver
- 1.Cattoir L, VAN HOECKE F, Van Maerken T, Nys E, Ryckaert I, De Boulle M, et al. Hepatitis E virus serology and PCR : does the methodology matter? ARCHIVES OF VIROLOGY. 2017;162(9):2625–32.
- IEEE
- [1]L. Cattoir et al., “Hepatitis E virus serology and PCR : does the methodology matter?,” ARCHIVES OF VIROLOGY, vol. 162, no. 9, pp. 2625–2632, 2017.
@article{8530523,
abstract = {{Hepatitis E virus (HEV) genotype 3 is an emerging pathogen in the developed world. As the clinical manifestations and routine laboratory parameters are often nonspecific, accurate diagnostic tests are crucial. In the current study, the performance of six serological assays and three PCR assays for the detection of HEV was evaluated. In the setting of the Ghent University Hospital, patients with clinically suspected HEV infection were tested for the presence of HEV IgM and IgG as well as HEV RNA. Serology was performed using six commercial HEV ELISA assays: Biorex, Wantai and Mikrogen IgM and IgG. HEV RNA was detected using one commercial assay (Altona RealStarA (R)), and two optimized in-house real-time RT-PCR assays (according to Jothikumar et al., 2006 and Gyarmati et al., 2007). In addition, all three PCR assays were performed on 16 external quality control (EQC) samples. In a period of 39 months (January 2011-April 2014), 70 patients were enrolled. Using different ELISA assays, the prevalence of antibodies varied from 5.7% to 14.3% for HEV IgM and from 15.7% to 20.0% for IgG. All but two of the results of the PCR assays performed on clinical samples agreed. However, 10 out of 16 EQC samples results showed major discrepancies. We observed important differences in the performance of various serological and PCR assays. For this reason, results of both serological and molecular tests for HEV should be interpreted with caution.}},
author = {{Cattoir, Lien and VAN HOECKE, FREDERIK and Van Maerken, Tom and Nys, Eveline and Ryckaert, Inge and De Boulle, Matthias and Geerts, Anja and Verhelst, Xavier and Colle, Isabelle and Hutse, Veronik and Suin, Vanessa and Wautier, Magali and Van Gucht, Steven and Van Vlierberghe, Hans and Padalko, Elizaveta}},
issn = {{0304-8608}},
journal = {{ARCHIVES OF VIROLOGY}},
keywords = {{DEVELOPED-COUNTRIES,EMERGING INFECTION,ASSAYS,PERFORMANCE,DIAGNOSIS,DISEASE,RNA}},
language = {{eng}},
number = {{9}},
pages = {{2625--2632}},
title = {{Hepatitis E virus serology and PCR : does the methodology matter?}},
url = {{http://dx.doi.org/10.1007/s00705-017-3395-0}},
volume = {{162}},
year = {{2017}},
}
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: